Perkins commends forward-thinking MRFF priorities

The Harry Perkins Institute of Medical Research has welcomed an announcement from the Medical Research Future Fund (MRFF), highlighting a plan for healthcare priorities.

PerkinsThe comprehensive plan was revealed at the Association of Australian Medical Research Institutes (AAMRI) Convention, to support the vision of ‘a health system fully informed by quality health and medical research’.

The MRFF plan has identified six strategic platforms, such as enhanced data and infrastructure and a focus on improving health services and systems. 

Perkins Director, Professor Peter Leedman, commended the Australian Government’s vision and huge investment in the ‘transformational’ MRFF. 

“It is accepted internationally that a major foundation for an excellent, high quality healthcare system is a robust and sustainable medical research industry,” Professor Leedman said.

“Vibrant health and medical research cultures within hospitals and primary care lead to great medicine, with the best outcomes. With the transformational new Medical Research Future Fund strategy, we have an extraordinary opportunity to foster this across the entire sector,” he said.

Perkins Chief Operating Officer, John Fitzgerald, said the announcement was an important step towards creating health and economic benefits for the community.

“Australia needs to take steps towards bridging the gap between research, health services, industry and patients,” Mr. Fitzgerald said.

“Strategic investment is urgently needed to ensure that the pioneering medical research being produced in Australia, can be translated into health outcomes as quickly as possible.”

“This will improve the health of the community, build the economy and contribute to health system sustainability.”

The MRFF announcement acknowledged that it’s “not seeking to achieve everything” and instead identifies its role as “reinforcing the existing research pipeline and filling in some of the gaps in areas like health and services research and the ‘valley of death’ at the pre-clinical and the post proof-of-concept commercialisation stages.” 

Back To Top